Biology and Signal Transduction pathways of the Lymphotoxin-αβ/LTβR system

[en] This review focuses on the biological functions and signalling pathways activated by Lymphotoxin α (LTα)/Lymphotoxin β (LTβ) and their receptor LTβR. Genetic mouse models shed light on crucial roles for LT/LTβR to build and to maintain the architecture of lymphoid organs and to ensure an adapted immune response against invading pathogens. However, chronic inflammation, autoimmunity, cell death or cancer development are disorders that occur when the LT/LTβR system is twisted. Biological inhibitors, such as antagonist antibodies or decoy receptors, have been developed and used in clinical trials for diseases associated to the LT/LTβR system. Recent progress in the understanding of cellular trafficking and NF-κB signaling pathways downstream of LTα/LTβ may bring new opportunities to develop therapeutics that target the pathological functions of these cytokines.

Research Center/Unit :

Unit of Molecular Immunology and Signal Transduction

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Remouchamps, Caroline ; Université de Liège - ULiège > GIGA-R : Virologie - Immunologie

Boutaffala, Layla

Ganeff, Corinne

Dejardin, Emmanuel ; Université de Liège - ULiège > GIGA-R : Virologie - Immunologie

Language :

English

Title :

Biology and Signal Transduction pathways of the Lymphotoxin-αβ/LTβR system

Publication date :

2011

Journal title :

Cytokine and Growth Factor Reviews

ISSN :

1359-6101

Publisher :

Elsevier Science

Special issue title :

Cytokine research in Belgium

Volume :

Pages :

301-310

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

Télévie, FCC

Available on ORBi :

since 14 November 2011

Statistics

Number of views

137 (30 by ULiège)

Number of downloads

11 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Collette Y., Gilles A., Pontarotti P., Olive D. A co-evolution perspective of the TNFSF and TNFRSF families in the immune system. Trends in Immunology 2003, 24:387-394.
Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
Kuprash D.V., Boitchenko V.E., Yarovinsky F.O., Rice N.R., Nordheim A., Ruhlmann A., et al. blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells. Blood 2002, 100:1721-1727.
Kuprash D.V., Osipovich O.A., Pokholok D.K., Alimzhanov M.B., Biragyn A., Turetskaya R.L., et al. Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation. Journal of Immunology 1996, 156:2465-2472.
Voon D.C., Subrata L.S., Karimi M., Ulgiati D., Abraham L.J. TNF and phorbol esters induce lymphotoxin-beta expression through distinct pathways involving Ets and NF-kappa B family members. Journal of Immunology 2004, 172:4332-4341.
Lee S.H., Park S.G., Lim S.O., Jung G. The hepatitis B virus X protein up-regulates lymphotoxin alpha expression in hepatocytes. Biochimica et Biophysica Acta 2005, 1741:75-84.
Lowes K.N., Croager E.J., Abraham L.J., Olynyk J.K., Yeoh G.C. Upregulation of lymphotoxin beta expression in liver progenitor (oval) cells in chronic hepatitis C. Gut 2003, 52:1327-1332.
Subrata L.S., Lowes K.N., Olynyk J.K., Yeoh G.C., Quail E.A., Abraham L.J. Hepatic expression of the tumor necrosis factor family member lymphotoxin-beta is regulated by interleukin (IL)-6 and IL-1beta: transcriptional control mechanisms in oval cells and hepatoma cell lines. Liver International 2005, 25:633-646.
Cui C.Y., Hashimoto T., Grivennikov S.I., Piao Y., Nedospasov S.A., Schlessinger D. Ectodysplasin regulates the lymphotoxin-beta pathway for hair differentiation. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:9142-9147.
Knight J.C., Keating B.J., Kwiatkowski D.P. Allele-specific repression of lymphotoxin-alpha by activated B cell factor-1. Nature Genetics 2004, 36:394-399.
Wicks K., Knight J.C. Transcriptional repression and DNA looping associated with a novel regulatory element in the final exon of the lymphotoxin-beta gene. Genes and Immunity 2011, 12:126-135.
Aggarwal B.B., Natarajan K. Tumor necrosis factors: developments during the last decade. European Cytokine Network 1996, 7:93-124.
Santee S.M., Owen-Schaub L.B. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. Journal of Biological Chemistry 1996, 271:21151-21159.
Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annual Review of Immunology 2005, 23:787-819.
Browning J.L., French L.E. Visualization of lymphotoxin-beta and lymphotoxin-beta receptor expression in mouse embryos. Journal of Immunology 2002, 168:5079-5087.
Kwon B.S., Tan K.B., Ni J., Oh K.O., Lee Z.H., Kim K.K., et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. Journal of Biological Chemistry 1997, 272:14272-14276.
Hashimoto T., Schlessinger D., Cui C.Y. Troy binding to lymphotoxin-alpha activates NF kappa B mediated transcription. Cell Cycle 2008, 7:106-111.
Androlewicz M.J., Browning J.L., Ware C.F. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. Journal of Biological Chemistry 1992, 267:2542-2547.
Eck M.J., Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6Å resolution. Implications for receptor binding. The Journal of Biological Chemistry 1989, 264:17595-17605.
Eck M.J., Ultsch M., Rinderknecht E., de Vos A.M., Sprang S.R. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-å resolution. The Journal of Biological Chemistry 1992, 267:2119-2122.
Jones E.Y., Stuart D.I., Walker N.P. Structure of tumour necrosis factor. Nature 1989, 338:225-228.
Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55kDa TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.
Eby M.T., Jasmin A., Kumar A., Sharma K., Chaudhary P.M. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. The Journal of Biological Chemistry 2000, 275:15336-15342.
Force W.R., Glass A.A., Benedict C.A., Cheung T.C., Lama J., Ware C.F. Discrete signaling regions in the lymphotoxin-beta receptor for tumor necrosis factor receptor-associated factor binding, subcellular localization, and activation of cell death and NF-kappaB pathways. Journal of Biological Chemistry 2000, 275:11121-11129.
Ganeff C., Remouchamps C., Boutaffala L., Benezech C., Galopin G., Vandepaer S., et al. Induction of the alternative NF-{kappa}B pathway by Lymphotoxin {alpha}{beta} (LT{alpha}{beta}) relies on internalization of LT{beta} receptor. Molecular and Cellular Biology 2011, 31:4319-4334.
Grech A.P, Gardam S., Chan T., Quinn R., Gonzales R., Basten A., et al. Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. Journal of Biological Chemistry 2005, 280:31572-31581.
Marsters S.A., Ayres T.M., Skubatch M., Gray C.L., Rothe M., Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. Journal of Biological Chemistry 1997, 272:14029-14032.
Naito A., Yoshida H., Nishioka E., Satoh M., Azuma S., Yamamoto T., et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8766-8771.
Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
Loetscher H., Stueber D., Banner D., Mackay F., Lesslauer W. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. The Journal of Biological Chemistry 1993, 268:26350-26357.
Van Ostade X., Tavernier J., Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Engineering 1994, 7:5-22.
Williams-Abbott L., Walter B.N., Cheung T.C., Goh C.R., Porter A.G., Ware C.F. The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand. The Journal of Biological Chemistry 1997, 272:19451-19456.
Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. The Journal of Clinical Investigation 1998, 102:1142-1151.
Rooney I.A., Butrovich K.D., Glass A.A., Borboroglu S., Benedict C.A., Whitbeck J.C., et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. The Journal of Biological Chemistry 2000, 275:14307-14315.
Crowe P.D., VanArsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 1994, 264:707-710.
Bossen C., Ingold K., Tardivel A., Bodmer J.L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. The Journal of Biological Chemistry 2006, 281:13964-13971.
Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
Young J., Yu X., Wolslegel K., Nguyen A., Kung C., Chiang E., et al. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51:78-86.
Granger S.W., Butrovich K.D., Houshmand P., Edwards W.R., Ware C.F. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. Journal of Immunology 2001, 167:5122-5128.
Crowe P.D., VanArsdale T.L., Goodwin R.G., Ware C.F. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation. Journal of Immunology 1993, 151:6882-6890.
Reddy P., Slack J.L., Davis R., Cerretti D.P., Kozlosky C.J., Blanton R.A., et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. The Journal of Biological Chemistry 2000, 275:14608-14614.
Solomon K.A., Pesti N., Wu G., Newton R.C. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. Journal of Immunology 1999, 163:4105-4108.
Levine S.J., Adamik B., Hawari F.I., Islam A., Yu Z.X., Liao D.W., et al. Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells. American Journal of Physiology: Lung Cellular and Molecular Physiology 2005, 289:L233-L243.
Xia M., Xue S.B., Xu C.S. Shedding of TNFR1 in regenerative liver can be induced with TNF alpha and PMA. World Journal of Gastroenterology 2002, 8:1129-1133.
Yu M., Lam J., Rada B., Leto T.L., Levine S.J. Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways. Journal of Immunology 2011, 186:1180-1188.
Cui X., Hawari F., Alsaaty S., Lawrence M., Combs C.A., Geng W., et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. The Journal of Clinical Investigation 2002, 110:515-526.
Islam A., Adamik B., Hawari F.I., Ma G., Rouhani F.N., Zhang J., et al. Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. The Journal of Biological Chemistry 2006, 281:6860-6873.
Hawari F.I., Rouhani F.N., Cui X., Yu Z.X., Buckley C., Kaler M., et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1297-1302.
Islam A., Jones H., Hiroi T., Lam J., Zhang J., Moss J., et al. cAMP-dependent protein kinase A (PKA) signaling induces TNFR1 exosome-like vesicle release via anchoring of PKA regulatory subunit RIIbeta to BIG2. The Journal of Biological Chemistry 2008, 283:25364-25371.
Zhang J., Hawari F.I., Shamburek R.D., Adamik B., Kaler M., Islam A., et al. Circulating TNFR1 exosome-like vesicles partition with the LDL fraction of human plasma. Biochemical and Biophysical Research Communications 2008, 366:579-584.
McDermott M.F, Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
Fischer R., Maier O., Naumer M., Krippner-Heidenreich A., Scheurich P., Pfizenmaier K. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFkappaB pathway. Cellular Signalling 2011, 23:161-170.
Edeling M.A., Smith C., Owen D. Life of a clathrin coat: insights from clathrin and AP structures. Nature Reviews Molecular Cell Biology 2006, 7:32-44.
Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunological Reviews 2011, 244:9-28.
Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
Schneider-Brachert W., Tchikov V., Merkel O., Jakob M., Hallas C., Kruse M.L., et al. Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. The Journal of Clinical Investigation 2006, 116:2901-2913.
Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochemical Pharmacology 2006, 72:1161-1179.
Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
Xiao G., Harhaj E.W., Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Molecular Cell 2001, 7:401-409.
Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. Journal of Biological Chemistry 2004, 279:26243-26250.
Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nature Immunology 2008, 9:1364-1370.
Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nature Immunology 2008, 9:1371-1378.
Sanjo H., Zajonc D.M., Braden R., Norris P.S., Ware C.F. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. The Journal of Biological Chemistry 2010, 285:17148-17155.
Banks T.A., Rouse B.T., Kerley M.K., Blair P.J., Godfrey V.L., Kuklin N.A., et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. Journal of Immunology 1995, 155:1685-1693.
De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994, 264:703-707.
Wang H., Feng J., Qi C., Morse H.C. An ENU-induced mutation in the lymphotoxin alpha gene impairs organogenesis of lymphoid tissues in C57BL/6 mice. Biochemical and Biophysical Research Communications 2008, 370:461-467.
Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., et al. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:9302-9307.
Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6:491-500.
Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. Journal of Experimental Medicine 2002, 195:1613-1624.
Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. The Journal of Experimental Medicine 1996, 184:1397-1411.
Kuprash D.V., Tumanov A.V., Liepinsh D.J., Koroleva E.P., Drutskaya M.S., Kruglov A.A., et al. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. European Journal of Immunology 2005, 35:1592-1600.
Neumann B., Luz A., Pfeffer K., Holzmann B. Defective Peyer's patch organogenesis in mice lacking the 55-kDa receptor for tumor necrosis factor. Journal of Experimental Medicine 1996, 184:259-264.
Pasparakis M., Alexopoulou L., Grell M., Pfizenmaier K., Bluethmann H., Kollias G. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6319-6323.
Futterer A., Mink K., Luz A., Kosco-Vilbois M.H., Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998, 9:59-70.
Rennert P.D., Browning J.L., Mebius R., Mackay F., Hochman P.S. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. Journal of Experimental Medicine 1996, 184:1999-2006.
Adachi S., Yoshida H., Kataoka H., Nishikawa S. Three distinctive steps in Peyer's patch formation of murine embryo. International Immunology 1997, 9:507-514.
Mebius R.E., Rennert P., Weissman I.L. Developing lymph nodes collect CD4+CD3-LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997, 7:493-504.
Randall T.D., Carragher D.M., Rangel-Moreno J. Development of secondary lymphoid organs. Annual Review of Immunology 2008, 26:627-650.
Yoshida H., Naito A., Inoue J., Satoh M., Santee-Cooper S.M., Ware C.F., et al. Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches. Immunity 2002, 17:823-833.
Alcamo E., Hacohen N., Schulte L.C., Rennert P.D., Hynes R.O., Baltimore D. Requirement for the NF-kappaB family member RelA in the development of secondary lymphoid organs. Journal of Experimental Medicine 2002, 195:233-244.
Shinkura R., Kitada K., Matsuda F., Tashiro K., Ikuta K., Suzuki M., et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nature Genetics 1999, 22:74-77.
Yin L., Wu L., Wesche H., Arthur C.D., White J.M., Goeddel D.V., et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 2001, 291:2162-2165.
Burkly L., Hession C., Ogata L., Reilly C., Marconi L.A., Olson D., et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995, 373:531-536.
Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995, 80:331-340.
Caamano J.H., Rizzo C.A., Durham S.K., Barton D.S., Raventos-Suarez C., Snapper C.M., et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. Journal of Experimental Medicine 1998, 187:185-196.
Franzoso G., Carlson L., Poljak L., Shores E.W., Epstein S., Leonardi A., et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. Journal of Experimental Medicine 1998, 187:147-159.
Miosge L.A., Blasioli J., Blery M., Goodnow C.C. Analysis of an ethylnitrosourea-generated mouse mutation defines a cell intrinsic role of nuclear factor kappaB2 in regulating circulating B cell numbers. Journal of Experimental Medicine 2002, 196:1113-1119.
Lo J.C., Basak S., James E.S., Quiambo R.S., Kinsella M.C., Alegre M.L., et al. Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 2006, 107:1048-1055.
Sha W.C., Liou H.-C., Tuomanen E.I., Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995, 80:321-330.
Tucker E., O'Donnell K., Fuchsberger M., Hilton A.A., Metcalf D., Greig K., et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor" Journal of Immunology 2007, 179:7514-7522.
Alexopoulou L., Pasparakis M., Kollias G. Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function. The Journal of Experimental Medicine 1998, 188:745-754.
Sacca R., Turley S., Soong L., Mellman I., Ruddle N.H. Transgenic expression of lymphotoxin restores lymph nodes to lymphotoxin-alpha-deficient mice. Journal of Immunology 1997, 159:4252-4260.
Liepinsh D.J., Grivennikov S.I., Klarmann K.D., Lagarkova M.A., Drutskaya M.S., Lockett S.J., et al. Novel Lymphotoxin alpha (LT{alpha}) knockout mice with unperturbed tumor necrosis factor expression: reassessing LT{alpha} biological functions. Molecular and Cellular Biology 2006, 26:4214-4225.
Tumanov A.V., Kuprash D.V., Nedospasov S.A. The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. Cytokine and Growth Factor Review 2003, 14:275-288.
Weih F., Caamano J. Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunological Reviews 2003, 195:91-105.
Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Reviews Immunology 2006, 6:205-217.
Drayton D.L., Liao S., Mounzer R.H., Ruddle N.H. Lymphoid organ development: from ontogeny to neogenesis. Nature Immunology 2006, 7:344-353.
Picarella D.E., Kratz A., Li C.B., Ruddle N.H., Flavell R.A. Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10036-10040.
Kratz A., Campos-Neto A., Hanson M.S., Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. The Journal of Experimental Medicine 1996, 183:1461-1472.
Mounzer R.H., Svendsen O.S., Baluk P., Bergman C.M., Padera T.P., Wiig H., et al. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood 2010, 116:2173-2182.
Sacca R., Cuff C.A., Lesslauer W., Ruddle N.H. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. Journal of Immunology 1998, 160:485-491.
Drayton D.L., Ying X., Lee J., Lesslauer W., Ruddle N.H., Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. Journal of Experimental Medicine 2003, 197:1153-1163.
Guerder S., Picarella D.E., Linsley P.S., Flavell R.A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:5138-5142.
Heikenwalder M., Prinz M., Zeller N., Lang K.S., Junt T., Rossi S., et al. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. American Journal of Pathology 2008, 172:1555-1570.
Liepinsh D.J., Kruglov A.A., Galimov A.R., Shakhov A.N., Shebzukhov Y.V., Kuchmiy A.A., et al. Accelerated thymic atrophy as a result of elevated homeostatic expression of the genes encoded by the TNF/lymphotoxin cytokine locus. European Journal of Immunology 2009, 39:2906-2915.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
Chen C.M., You L.R., Hwang L.H., Lee Y.H. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. Journal of Virology 1997, 71:9417-9426.
Matsumoto M., Hsieh T.Y., Zhu N., VanArsdale T., Hwang S.B., Jeng K.S., et al. virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. Journal of Virology 1997, 71:1301-1309.
You L.R., Chen C.M., Lee Y.H., Hepatitis C virus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha. Journal of Virology 1999, 73:1672-1681.
Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G., Ware C., et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. Journal of Virology 1998, 72:3691-3697.
Heikenwalder M., Zeller N., Seeger H., Prinz M., Klohn P.C., Schwarz P., et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005, 307:1107-1110.
Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.